Hydrogel used to revert cancer cells back to cancer stem cells
A new hydrogel has been shown to convert cancer cells to cancer stem cells within 24 hours, in six different human cancer cell line types.
A hydrogel developed at Hokkaido University, Japan, successfully reverted cancer cells back to cancer stem cells within 24 hours, in six different human cancer types. According to the researchers, this could lead to the development of anticancer stem cell drugs and personalised medicines.
Despite the advancement of treatments, the survival rate of patients with advanced-stage cancer remains low. One reason is that cancer tissues contain cancer stem cells, which are resistant to chemotherapies and radiotherapies. These cells can hide as ‘roots’ or circulate in the body, causing cancer recurrence.
“Cancer stem cells are a major target for anticancer drugs, but they are difficult to identify because they are present in very small numbers in cancer tissues,” explained Professor Shinya Tanaka, one of the lead researchers. “Understanding the molecular mechanisms of these stem cells is crucial for developing better cancer treatments.”
In the new study, the research team investigated whether their new double network (DN) gel could recreate the right conditions to induce cancer stem cells. The DN gel consists of a network of two chemicals and incorporates a high volume of water, giving it soft and wet characteristics resembling biological tissues.
The researchers found that the DN gel rapidly reprogrammed differentiated cancer cells into cancer stem cells in just 24 hours in six different human cancer cell lines – brain cancer, uterine cancer, lung cancer, colon cancer, bladder cancer and sarcoma. After cancer cells were placed on the DN gel, they started to form spherical structures and produce specific molecules known to be markers of cancer stem cells such as SOX2 and Oct3/4, aka Yamanaka factors, suggesting that they had been reprogrammed.
The researchers also uncovered some of the molecular mechanisms involved in cancer cell reprogramming. They found that calcium channel receptors and the protein osteopontin were essential for the induction of stem cells. They also discovered that brain cancer cells from a patient that had been cultured on the DN gel produced receptors called platelet-derived growth factor receptors. By adding a molecular inhibitor of these receptors, they were able to target and eradicate the cancer stem cells, suggesting that the DN gel could be used to select therapeutic drugs. In addition, they showed that the brain cancer cells that had been cultured on DN gel formed tumours efficiently when transplanted into mice brain, suggesting the stemness of the cancer cells.
The team say this study paves the way for research into drugs that can target cancer stem cells.
“In the future, the DN gel could be used to enhance cancer cell type diagnosis and to produce personalised medicines, which could improve the prognosis of cancer patients,” said Tanaka.
The findings were published in Nature Biomedical Engineering.